Practice test question

Question 1

What is the primary purpose of the Good Publication Practice (GPP) guidelines?
A) To increase the number of publications from a company
B) To promote transparency and integrity in medical publications
C) To ensure rapid publication of clinical trial results
D) To restrict access to unpublished data

Answer 1

B) To promote transparency and integrity in medical publications

Question 2

Who is typically responsible for determining authorship in a large clinical study?
A) The sponsor’s marketing team
B) The publication steering committee or author adjudication working group
C) The journal editor
D) The clinical trial principal investigator only

Answer 2

B) The publication steering committee or author adjudication working group

Question 3

Which of the following is NOT a criterion for authorship according to ICMJE guidelines?
A) Substantial contributions to study design or data interpretation
B) Drafting or revising the manuscript critically
C) Providing funding for the study
D) Approval of the final version to be published

Answer 3

C) Providing funding for the study

Question 4

Publications that analyze previously published data without generating new data require which of the following?
A) An author from the original publication
B) No author from the original publication
C) Approval from the original publication’s sponsor
D) A letter of permission from the original authors

Answer 4

B) No author from the original publication

Question 5

5. What role should colleagues primarily involved in sales or marketing play in biomedical publication content?
   A) Lead authorship
   B) Content development and review
   C) No influence on content development, review, or approval
   D) Final approval of manuscripts

Answer 5

C) No influence on content development, review, or approval

Question 6

What is the recommended timing for the publication working group kick-off meeting?
A) After study data are published
B) Before study data become available
C) After manuscript submission
D) After journal acceptance

Answer 6

B) Before study data become available

Question 7

7. During a publication working group kick-off meeting, what process should be reviewed to handle disagreements?
   A) Data analysis plan
   B) Dispute arbitration, escalation, and mediation process
   C) Budget allocation for publications
   D) Marketing strategy

Answer 7

B) Dispute arbitration, escalation, and mediation process

Question 8

8. What should be included in a conflict of interest (COI) disclosure?
   A) Only financial relationships with the sponsor
   B) All financial and non-financial relationships relevant to the work
   C) Only consulting fees
   D) Only relationships with academic institutions

Answer 8

B) All financial and non-financial relationships relevant to the work

Question 9

What does RWE stand for in medical publications?
A) Real-World Evidence
B) Research Writing Ethics
C) Regulatory Writing Elements
D) Randomized Workflow Evaluation

Answer 9

A) Real-World Evidence

Question 10

According to GPP, colleagues performing HEOR or medical affairs functions are considered:
A) Commercial professionals
B) Researchers
C) Marketing specialists
D) Journal editors

Answer 10

B) Researchers

Question 11

Which statement about preprints is TRUE?
A) Preprints have undergone full peer review
B) Preprints are publicly accessible versions of research before peer review
C) Preprints cannot be cited in publications
D) Preprints are confidential internal documents

Answer 11

B) Preprints are publicly accessible versions of research before peer review

Question 12

What is the primary reason for having a publication steering committee (SC)?
A) To manage marketing activities for publications
B) To oversee and coordinate publication activities and authorship decisions
C) To write all manuscripts
D) To review clinical trial protocols

Answer 12

B) To oversee and coordinate publication activities and authorship decisions

Question 13

When conflicts arise in authorship or publication content, what is the best initial step?
A) Ignore the conflict and proceed
B) Hold a consensus meeting to reconcile differing opinions
C) Remove dissenting members from the team
D) Submit the manuscript without consensus

Answer 13

B) Hold a consensus meeting to reconcile differing opinions

Question 14

What is the purpose of posting clinical trial results in registries?
A) To restrict data access to sponsors
B) To enhance data transparency and public access
C) To promote specific products
D) To delay publication

Answer 14

B) To enhance data transparency and public access

Question 15

What should happen if a publication professional identifies a compliance issue during manuscript development?
A) Proceed without changes to meet deadlines
B) Address the issue and discuss it with the team to ensure compliance
C) Remove the problematic content without discussion
D) Inform the marketing department only

Answer 15

B) Address the issue and discuss it with the team to ensure compliance

Question 16

What does “byline authorship” refer to?
A) Individuals listed as authors on a publication
B) Reviewers of the manuscript
C) Journal editorial board members
D) Study participants

Answer 16

A) Individuals listed as authors on a publication

Question 17

Which of the following is TRUE about meetings during the publication process?
A) They are only needed before manuscript submission
B) They can include discussions on publication content, data interpretation, and additional analyses
C) They should be avoided to save time
D) Only the sponsor attends these meetings

Answer 17

B) They can include discussions on publication content, data interpretation, and additional analyses

Question 18

Why is it important to assign roles and responsibilities early in the publication process?
A) To ensure clear accountability and efficient workflow
B) To delay manuscript writing
C) To reduce the number of authors
D) To comply with journal formatting

Answer 18

A) To ensure clear accountability and efficient workflow

Question 19

Which of the following is an example of an ethical concern in medical publishing?
A) Transparent disclosure of funding sources
B) Ghostwriting without proper author acknowledgment
C) Timely dissemination of study results
D) Peer review of manuscripts

Answer 19

B) Ghostwriting without proper author acknowledgment

Question 20

What is the best way to handle data interpretation disagreements among authors?
A) Exclude dissenting authors from the manuscript
B) Hold a consensus meeting to discuss and resolve differences
C) Publish only the majority opinion
D) Remove the conflicting data

Answer 20

B) Hold a consensus meeting to discuss and resolve differences

Question 21

Which of the following is NOT a primary responsibility of a publication professional?
A) Ensuring compliance with GPP guidelines
B) Writing marketing copy for product advertisements
C) Managing publication planning timelines
D) Ensuring accuracy and transparency in scientific data

Answer 21

B) Writing marketing copy for product advertisements

Question 22

According to GPP, who is ultimately responsible for the content of a manuscript?
A) The corresponding author
B) The medical writer
C) The sponsor
D) The publication steering committee

Answer 22

A) The corresponding author

Question 23

Which of the following is considered an unethical authorship practice?
A) Including a contributor who meets all ICMJE authorship criteria
B) Listing an author who provided only funding but no intellectual contribution
C) Providing authors with full access to data
D) Ensuring authors approve the final manuscript

Answer 23

B) Listing an author who provided only funding but no intellectual contribution

Question 24

What is the main purpose of a publication plan?
A) To outline marketing strategies for product promotion
B) To detail the schedule and tactics for disseminating scientific and clinical data
C) To manage FDA submissions
D) To monitor social media feedback

Answer 24

B) To detail the schedule and tactics for disseminating scientific and clinical data

Question 25

Which of the following best defines "ghostwriting"? A) When a medical writer drafts content under the supervision of all authors B) When a person who made substantial contributions is not acknowledged or listed as an author C) When an external writer edits for grammar D) When the sponsor provides raw data to authors

Answer 25

B) When a person who made substantial contributions is not acknowledged or listed as an author

Question 26

According to ICMJE criteria, which is NOT a requirement for authorship? A) Significant contributions to the conception or design of the work B) Drafting or revising the work critically C) Approval of the final version D) Financial compensation for writing the manuscript

Answer 26

D) Financial compensation for writing the manuscript

Question 27

What is the recommended approach if an author requests adding data post-acceptance? A) Submit a correction or erratum to the journal B) Modify the proofs directly without informing the journal C) Publish a new preprint with the updated data D) Wait until the next publication

Answer 27

A) Submit a correction or erratum to the journal

Question 28

Which document type is typically used to communicate key data to healthcare providers and payers in a concise, visual way? A) Abstract B) Slide deck C) Manuscript D) Lay summary

Answer 28

B) Slide deck

Question 29

When is it appropriate for a sponsor to review a manuscript? A) Before the authors have drafted it B) After journal acceptance C) To verify factual accuracy, data integrity, and compliance before submission D) To approve the language for marketing claims

Answer 29

C) To verify factual accuracy, data integrity, and compliance before submission

Question 30

Which of the following should be included in a conflict of interest (COI) disclosure? A) Only financial relationships within the past 3 months B) Financial and non-financial relationships relevant to the content C) Only relationships with the current sponsor D) None of the above

Answer 30

B) Financial and non-financial relationships relevant to the content

Question 31

What is the typical role of a publication steering committee? A) To promote marketing strategies for new drugs B) To oversee publication strategy, ensure accuracy, and review major deliverables C) To enforce ICMJE penalties D) To select journal editors

Answer 31

B) To oversee publication strategy, ensure accuracy, and review major deliverables

Question 32

Which of the following is a key principle of data transparency? A) Withholding negative trial results B) Ensuring only positive outcomes are published C) Providing accurate and balanced data sharing with authors, journals, and trial registries D) Publishing only when favorable peer reviews are guaranteed

Answer 32

C) Providing accurate and balanced data sharing with authors, journals, and trial registries

Question 33

Which type of publication is most commonly associated with phase III clinical trial results? A) Narrative review B) Original research article C) Editorial D) Case report

Answer 33

B) Original research article

Question 34

According to GPP, which statement about preprints is correct? A) Authors should always post preprints of company-sponsored clinical trials B) GPP discourages proactive preprint posting by authors of company-sponsored trials C) Preprints must be withdrawn once peer review is complete D) Preprints replace the need for journal submissions

Answer 34

B) GPP discourages proactive preprint posting by authors of company-sponsored trials

Question 35

Which of these is NOT a responsibility of the corresponding author? A) Coordinating communication with the journal B) Managing social media requests from publishers C) Ensuring all co-authors have reviewed and approved the manuscript D) Ensuring promotional claims are added to the manuscript

Answer 35

D) Ensuring promotional claims are added to the manuscript

Question 36

Which of the following is the most appropriate reason to fund a journal supplement? A) To highlight only the sponsor’s products B) To support a thematic issue with a strong scientific rationale C) To influence prescribing behaviors D) To bypass peer review

Answer 36

B) To support a thematic issue with a strong scientific rationale

Question 37

A medical writer must: A) Be listed as an author for all publications they draft B) Disclose their contributions and funding source in the acknowledgments C) Remain anonymous to ensure impartiality D) Approve the manuscript after peer review

Answer 37

B) Disclose their contributions and funding source in the acknowledgments

Question 38

Which of these practices is considered part of fostering publication ethics? A) Adjusting data to fit the desired outcome B) Ensuring proper author disclosures and acknowledgments C) Submitting manuscripts to predatory journals D) Withholding the protocol from co-authors

Answer 38

B) Ensuring proper author disclosures and acknowledgments

Question 39

What is the main reason to document the publication development process? A) To comply with audit requirements and ensure accountability B) To satisfy journal reviewers’ curiosity C) To provide authors with marketing talking points D) To shorten the peer review process

Answer 39

A) To comply with audit requirements and ensure accountability

Question 40

What should authors do when journals post accepted manuscripts or preprints? A) Request immediate removal of preprints B) Verify that the correct version is posted C) Ignore these postings D) Submit an alternative manuscript

Answer 40

B) Verify that the correct version is posted

Question 41

Which of the following best describes the role of the medical publication professional (MPP)? A. To ensure the company’s marketing message is included in every publication. B. To plan, develop, and review publications in compliance with GPP and ethical standards. C. To act as the corresponding author for all company-sponsored publications. D. To approve all scientific content without author input.

Answer 41

B. To plan, develop, and review publications in compliance with GPP and ethical standards.

Question 42

Which of the following is NOT an ICMJE authorship criterion? A. Substantial contributions to conception or design of the work. B. Drafting or revising the manuscript for important intellectual content. C. Final approval of the version to be published. D. Having read the article before submission.

Answer 42

D. Having read the article before submission.

Question 43

According to GPP, which statement about acknowledgments is correct? A. Medical writers should never be acknowledged. B. Professional medical writers may be acknowledged for their contributions if they do not qualify for authorship. C. Only employees of the sponsor can be acknowledged. D. Acknowledgments are not required if a medical writer contributed only minor edits.

Answer 43

B. Professional medical writers may be acknowledged for their contributions if they do not qualify for authorship.

Question 44

Which of the following best describes the difference between predatory and legitimate journals? A. Predatory journals have higher impact factors. B. Legitimate journals always charge no fees. C. Predatory journals use deceptive practices and lack proper peer review. D. Legitimate journals are only published by large publishing houses.

Answer 44

C. Predatory journals use deceptive practices and lack proper peer review.

Question 45

What is the primary purpose of a publication plan? A. To identify marketing messages. B. To outline a strategy for disseminating data ethically and effectively across various publications and audiences. C. To guarantee all authors receive payment for their work. D. To set strict deadlines for marketing launches.

Answer 45

B. To outline a strategy for disseminating data ethically and effectively across various publications and audiences.

Question 46

Which of the following is considered an unethical authorship practice? A. Ghost authorship. B. Collaborative manuscript writing with author input. C. Reviewing a manuscript draft for accuracy. D. Following ICMJE criteria for authorship.

Answer 46

A. Ghost authorship.

Question 47

Which of the following is true regarding data sharing in clinical research? A. Data sharing is only required for studies with negative outcomes. B. Data sharing increases transparency and trust in scientific research. C. Data sharing must always include patient names. D. Data sharing violates all confidentiality regulations.

Answer 47

B. Data sharing increases transparency and trust in scientific research.

Question 48

According to GPP, which of these is recommended for managing publication steering committees? A. Include only sponsor employees. B. Ensure diverse expertise, clear roles, and transparent decision-making. C. Rotate members for every manuscript draft. D. Limit participation to one author per country.

Answer 48

B. Ensure diverse expertise, clear roles, and transparent decision-making.

Question 49

What is the recommended way to handle publication disputes between authors? A. Ignore the conflict and proceed with submission. B. Seek guidance from publication policies and, if necessary, escalate to the publication steering committee or ethics board. C. Allow the sponsor to make the final decision without author input. D. Assign authorship order based on company hierarchy.

Answer 49

B. Seek guidance from publication policies and, if necessary, escalate to the publication steering committee or ethics board.

Question 50

Which of the following best defines "guest authorship"? A. An author who contributed significantly but prefers to remain anonymous. B. Including an author who did not make substantial contributions to meet ICMJE criteria. C. Recognizing a sponsor employee for financial support. D. Listing an author posthumously.

Answer 50

B. Including an author who did not make substantial contributions to meet ICMJE criteria.

Question 51

Which section of a manuscript typically includes details on ethics approval and informed consent? A. Methods. B. Introduction. C. Results. D. Acknowledgments.

Answer 51

A. Methods.

Question 52

Which of the following would be considered a conflict of interest (COI)? A. An author owning stock in the company that funded the research. B. An author writing a draft with a professional medical writer. C. A medical writer editing for grammar. D. Submitting the manuscript to more than one journal.

Answer 52

A. An author owning stock in the company that funded the research.

Question 53

What is the main function of the ICMJE recommendations? A. To replace peer review. B. To provide guidelines for ethical authorship, manuscript preparation, and publication. C. To ensure all journals have the same submission system. D. To evaluate study design.

Answer 53

B. To provide guidelines for ethical authorship, manuscript preparation, and publication.

Question 54

Which of the following is NOT typically included in a trial registry (e.g., ClinicalTrials.gov)? A. Study design and endpoints. B. Primary outcomes. C. Names of all peer reviewers. D. Sponsor and investigator information.

Answer 54

C. Names of all peer reviewers.

Question 55

When is it acceptable to submit the same manuscript to multiple journals simultaneously? A. Only if all authors agree. B. If the study was industry funded. C. Only after the first journal declines the manuscript. D. Always, to speed up acceptance.

Answer 55

C. Only after the first journal declines the manuscript.

Question 56

What is the main benefit of using a professional medical writer? A. To manipulate data to match marketing goals. B. To improve clarity, accuracy, and compliance with guidelines. C. To ensure authors do not need to review drafts. D. To bypass peer review.

Answer 56

B. To improve clarity, accuracy, and compliance with guidelines.

Question 57

According to GPP, how should sponsors influence the content of a manuscript? A. They should dictate all conclusions. B. They should collaborate with authors but allow authors full control over interpretation and content. C. They should remove author names to avoid bias. D. They should only approve the abstract.

Answer 57

B. They should collaborate with authors but allow authors full control over interpretation and content.

Question 58

Which of these is NOT a principle of GPP? A. Transparency in authorship and contributions. B. Timely publication of results. C. Use of promotional tone in scientific articles. D. Ethical acknowledgment of all contributors.

Answer 58

C. Use of promotional tone in scientific articles.

Question 59

What is a “data-sharing statement” as required by ICMJE? A. A statement that explains how the authors analyzed the data. B. A statement indicating whether de-identified data will be shared, how, and when. C. A declaration of the manuscript’s funding source. D. A description of the journal’s peer review process.

Answer 59

B. A statement indicating whether de-identified data will be shared, how, and when.

Question 60

Which metric focuses on the attention an article receives across online platforms (e.g., social media)? A. Impact Factor. B. h-index. C. Altmetric Attention Score. D. Eigenfactor.

Answer 60

C. Altmetric Attention Score.

Question 61

Which core principle of GPP ensures that the publication process is free from bias and selective reporting? A) Transparency B) Accountability C) Authorship criteria D) Timeliness

Answer 61

A) Transparency

Question 62

Which of the following best defines the role of a publication steering committee (SC) under GPP? A) Approving the final draft only B) Guiding strategy, content, and data interpretation for publications C) Handling only journal selection D) Drafting manuscripts without input from authors

Answer 62

B) Guiding strategy, content, and data interpretation for publications

Question 63

Scenario: A sponsor suggests publishing only positive data and leaving out negative or inconclusive results. Question: Which GPP principle is violated? A) Reproducibility B) Transparency and completeness C) Journal ethics D) Authorship order

Answer 63

B) Transparency and completeness

Question 64

According to GPP, who is responsible for ensuring that professional medical writers are appropriately acknowledged? A) The sponsor only B) The corresponding author C) The medical writer themselves D) The journal editor

Answer 64

B) The corresponding author

Question 65

Scenario: A manuscript draft was written by a medical writer, but there is no acknowledgment of their contribution. Question: What is wrong? A) Nothing, as medical writers are not authors B) This is a violation of GPP transparency requirements C) The medical writer must be listed as first author D) The journal will automatically reject the paper

Answer 65

B) This is a violation of GPP transparency requirements

Question 66

Which of the following best describes the purpose of a publication plan under GPP? A) To outline marketing strategies for a drug B) To provide a structured approach to disseminating data accurately and ethically C) To decide which authors will be paid the most D) To ensure all publications are in high-impact journals

Answer 66

B) To provide a structured approach to disseminating data accurately and ethically

Question 67

Scenario: An author disagrees with how the sponsor interprets the clinical data. Question: What should happen according to GPP? A) Sponsor interpretation overrides author opinion B) Consensus should be sought among all authors C) The manuscript should be withdrawn D) The corresponding author makes the final call without discussion

Answer 67

B) Consensus should be sought among all authors

Question 68

Which of the following is NOT a key principle of GPP? A) Transparency B) Accountability C) Marketing alignment D) Completeness

Answer 68

C) Marketing alignment

Question 69

Scenario: A sponsor proposes submitting the same manuscript to multiple journals at once to speed publication. Question: Is this allowed under GPP? A) Yes, with sponsor approval B) No, because it constitutes duplicate submission C) Yes, but only for conference proceedings D) Yes, if the journal impact factor is below 5

Answer 69

B) No, because it constitutes duplicate submission

Question 70

Which statement about authorship is correct under GPP? A) All sponsor employees must be listed as authors B) Authorship must follow ICMJE criteria (substantial contributions, drafting, approval, and accountability) C) Medical writers should always be listed as authors D) Authorship is determined solely by the sponsor

Answer 70

B) Authorship must follow ICMJE criteria (substantial contributions, drafting, approval, and accountability)

Question 71

When is it acceptable to post a company-sponsored study on a preprint server under GPP? A) Only when approved by all authors and with transparent sponsor disclosure B) Never C) Only after peer review D) Only if the study is negative

Answer 71

A) Only when approved by all authors and with transparent sponsor disclosure

Question 72

Scenario: A global publication is planned, but regional publications are being developed first. Question: What risk must be managed? A) Duplicate publication and inconsistent messaging B) Regional bias in peer review C) Journal rejection due to small sample size D) A drop in impact factor

Answer 72

A) Duplicate publication and inconsistent messaging

Question 73

What is the role of professional medical writers under GPP? A) Drafting, editing, and ensuring compliance with GPP while being acknowledged appropriately B) Acting as the first author C) Approving final data analysis D) Reviewing manuscripts anonymously

Answer 73

A) Drafting, editing, and ensuring compliance with GPP while being acknowledged appropriately

Question 74

Which of the following is NOT recommended by GPP? A) Guest authorship (listing authors who did not contribute) B) Acknowledging all contributors, including writers C) Registering clinical trials and sharing results D) Publishing negative or inconclusive data

Answer 74

A) Guest authorship (listing authors who did not contribute)

Question 75

Scenario: A sponsor wants to delay publication until after product launch to maximize commercial benefit. Question: What should happen under GPP? A) Delay is acceptable for marketing purposes B) Data should be published in a timely manner regardless of marketing plans C) Authors can be paid to stay silent D) Wait until all authors retire

Answer 75

B) Data should be published in a timely manner regardless of marketing plans

Question 76

According to GPP, who is responsible for the accuracy of the manuscript? A) Sponsor company only B) Medical writer C) All authors collectively D) The journal editor

Answer 76

C) All authors collectively

Question 77

Scenario: During manuscript development, new safety data become available before submission. Question: What is the appropriate action? A) Ignore the new data to avoid delays B) Incorporate the new data to ensure completeness and accuracy C) Submit first and publish corrections later D) Delay indefinitely

Answer 77

B) Incorporate the new data to ensure completeness and accuracy

Question 78

Which of the following is part of proper disclosure under GPP? A) Listing sponsor funding, author conflicts, and professional writing support B) Only listing the journal’s preferred disclosures C) Declaring only positive data D) Hiding sponsor involvement

Answer 78

A) Listing sponsor funding, author conflicts, and professional writing support

Question 79

Scenario: A company wants to use clinical trial data in a journal supplement but has no medical rationale for publishing it as a supplement. Question: What is the issue? A) Supplements must have a strong scientific rationale to justify funding and publication B) Supplements are not allowed under GPP C) Supplements can only contain negative studies D) Supplements do not require peer review

Answer 79

A) Supplements must have a strong scientific rationale to justify funding and publication

Question 80

What is the recommended process if multiple authors disagree on the order of authorship? A) The sponsor decides B) Use a consensus-based approach among authors C) List authors alphabetically by default D) Allow the journal to decide

Answer 80

B) Use a consensus-based approach among authors